Boothbay Fund Management, LLC Mersana Therapeutics, Inc. Transaction History

Boothbay Fund Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $350,351 - $1.29 Million	330,520 Added 3296.96%	340,545 $432,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $30,877 - $95,738	10,025 New	10,025 $32,000
Q4 2021 Feb 14, 2022	SELL	$5.48 - $9.86 $124,746 - $224,453	-22,764 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $57,292 - $96,847	6,693 Added 41.65%	22,764 $215,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $213,422 - $290,402	16,071 New	16,071 $218,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $234,671 - $406,498	-15,328 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $258,123 - $422,899	15,328 New	15,328 $408,000
Q2 2020 Aug 14, 2020	SELL	$5.24 - $23.4 $63,404 - $283,140	-12,100 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $53,361 - $112,287	12,100 New	12,100 $71,000

126

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $57.3M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.